To include your compound in the COVID-19 Resource Center, submit it here.

Impavido miltefosine: Phase III; marketed in India to treat visceral Leishmaniasis

In a double-blind Phase III trial in 133 patients in Columbia

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE